Pancreatic Cancer
10 protocols meet the specified criteria
- OCR13631
Molecular Analysis for Therapy Choice (MATCH)
- OCR14759
A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically inoperable Pancreatic Adenocarcinoma.
- OCR15092
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
- OCR15253
A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy
- OCR15355
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
- OCR16937
A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors
- OCR17089
Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- OCR17279
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
- OCR17388
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
- OCR17458
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors